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Abstract 
Since the definite diagnosis of Creutzfeldt-Jakob disease (CJD) can currently only be provided 
by autopsy, there is a special need for fine diagnostic tools in live patients to achieve accurate 
diagnosis as early as possible. The aim of this study was to perform a preliminary retrospective 
analysis on the utility of the measurement of total Tau (tTau) and phosphorylated Tau (pTau) 
proteins, and b-amyloid peptide 1-42 (Ab1-42) from the cerebrospinal fluid (CSF) of patients 
with rapidly progressive dementia in the diagnostic work up of CJD. 
Beside the assessment of relevant clinical data and the findings of electroencephalography and 
brain magnetic resonance imaging, the presence of 14-3-3 protein and the levels of tTau, pTau, 
and Ab1-42 were determined by Western blot technique and enzyme-linked immunosorbent 
assay from the CSF of 19 patients diagnosed with rapidly progressive dementia between the 
period of 2004-2017 at the Department of Neurology, University of Szeged. 
This preliminary study provided 100% sensitivity and, interestingly, only 40% specificity 
values for the positivity of 14-3-3. Regarding tTau, the sensitivity values were calculated to be 
100% or 83%, whereas the specificity values were 71% or 86%, depending on the applied cut-
off levels. With regard to pTau and Ab1-42, all the calculated parameters were considerably poor, 
except for a relatively good specificity (86%) of pTau. 
The results of the current study tend to be in line with the literature data. The combined 
application of these and novel chemical biomarkers may increase both sensitivity and 
specificity to a desired level. 
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Absztrakt 
Mivel jelenleg csak a pathológiai vizsgálat nyújt biztos diagnózist a Creutzfeldt-Jakob betegség 
(CJB) vonatkozásában, ezért különösen nagy szükség van olyan tesztekre, melyek még élő 
állapotban szolgáltatnak megfelelő diagnózist lehetőleg a betegség kezdeti stádiumában. Jelen 
tanulmány célja egy előzetes retrospektív analízis végzése volt a gyorsan progrediáló 
demenciával diagnosztizált betegek liquor totál tau (tTau), foszforilált tau (pTau) és a b-amiloid 
peptid 1-42 (Ab1-42) szintjének CJB diagnosztikájában való használhatóságáról. 
A releváns klinikai adatok, valamint elektroenkefalográfiás és agyi mágneses magrezonanciás 
vizsgálati eredmények feldolgozása mellett a 14-3-3 fehérje kimutatása, továbbá a tTau, pTau 
és Ab1-42 szintek meghatározása Western blot, illetve enzimhez kapcsolt immunoszorbens 
vizsgálatokkal történt 19, a Szegedi Tudományegyetem Neurológiai Klinikáján 2004-2017 
között gyorsan progrediáló demenciával diagnosztizált beteg liquorából. 
A jelen előzetes tanulmány 100%-os szenzitivitást és meglepő módon, csak 40%-os 
specificitást mutatott a 14-3-3 fehérjére a CJB diagnosztikájában. A tTau esetén a szenzitivitás 
100%-nak, illetve 83%-nak, míg a specificitás 71%-nak, illetve 86%-nak adódott a használt 
referenciaértéktől függően. A pTau és Ab1-42 vonatkozásában a fenti kalkulált paraméterek 
meglehetősen alacsonyak voltak, kivéve a pTau jónak mondható specificitását (86%). 
Jelen vizsgálat eredményei jó összhangban vannak a szakirodalmi adatokkal. Valószínűleg a 
fenti anyagok és néhány új kémiai biomarker együttes alkalmazása a megfelelő szintre emelheti 
mind a szenzitivitást, mind a specificitást a CJB diagnosztikájában. 
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1. Introduction 
Human transmissible spongiform encephalopathies, which include Creutzfeldt-Jakob disease 
(CJD), Gerstmann-Sträussler-Scheinker disease (GSS), fatal familial insomnia (FFI), and kuru, 
are rare neurodegenerative disorders, out of which CJD is by far the most common (1-
2/1.000.000 person/year)1. Beside classic prion diseases, the prion-like propagation of the 
pathological process was raised in other neurodegenerative conditions, such as Alzheimer’s 
disease (AD) and Parkinson’s disease as well2. CJD is characterized by a rapid disease course 
associated with the conformational transformation of the human cellular prion protein (PrPc) 
into the neurotoxic, protease-resistant scrapie form of this protein (PrPSc)3. Considering the 
etiology of CJD, sporadic, familial, and acquired (variant and iatrogenic) forms are specified3,4. 
The sporadic form (sCJD) is the most common type, representing approximately 85% of all 
CJD cases with an unknown mechanism of infection5. It has 6 phenotypes, obtained from the 
combination of the methionine/valine (M/V) polymorphism in the coding region of the prion 
protein gene (PRNP) with the two isoforms of the PrPSc6–8. The genetic form of CJD (gCJD) 
accounts for 10-15% of the cases internationally9,10. The variant form of CJD (vCJD) shows a 
regional accumulation, mainly restricted to the United Kingdom and France, and it is known to 
be caused by consuming bovine spongiform encephalopathy-infected food11. The principal 
sources of iatrogenic CJD (iCJD) include contaminated growth hormone extracts and dura 
mater grafts derived from human cadavers with undiagnosed CJD infections, and it has an 
incidence of 1% of all CJD cases12. 
In addition to the presence of characteristic rapidly progressive dementia, the clinical picture 
may include the following clinical features: myoclonus, visual or cerebellar disturbance, 
pyramidal/extrapyramidal dysfunction, and akinetic mutism13. Along with typical 
electroencephalographic (EEG) findings during an illness of any duration AND/OR a positive 
14-3-3 cerebrospinal fluid (CSF) assay with a clinical duration to death < 2 years AND/OR 
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high signal abnormalities in the caudate nucleus and putamen or at least two cortical regions 
(temporal-parietal-occipital) either in DWI or FLAIR sequences IF routine investigations do 
not suggest an alternative diagnosis, the diagnosis of probable or possible CJD can be set up 
depending on the number of matching factors13,14. The diagnosis of definite CJD requires 
comprehensive post-mortem neuropathological assessment13. Although the current diagnostic 
criteria list only 14-3-3 as a biomarker, total tau (tTau), phosphorylated tau (pTau), α-synuclein, 
S100B protein15,16, prion proteins4, neuron-specific enolase (NSE)17,18, neurofilament light 
chain (NF-L), phosphorylated neurofilament heavy chain (pNF-H)19,20, and b-amyloid 
peptide20,21 were also assessed for their suitability as biomarkers (Fig. 1.). 
The presence of 14-3-3 protein in the CSF, which is characteristic of almost 95% of sCJD 
cases17, is usually determined by Western blot test. From the 7 known isomers (β, γ, ε, ζ, η, σ, 
and τ) only the presence of the β, γ, ε, and η forms has been demonstrated in CJD22. The tTau 
protein proved to be a useful biomarker in the diagnostic work up of different neurological 
diseases, including AD23 and CJD, and together with the presence of 14-3-3 protein, they can 
reliably support the clinical diagnosis15. The tTau protein is highly increased in CJD, whereas 
this characteristic elevation cannot be observed for pTau24,25. In addition to the above-
mentioned proteins, the levels of NF-L and pNF-H were found increased as well in both serum 
and CSF samples19,20,26–28. With regard to b-amyloid concentrations, similarly to AD, decreased 
values were reported compared to control groups25,29. It was demonstrated that S100B protein 
may have a role in the diagnosis of genetic prion diseases, including gCJD, GSS, and FFI, 
showing elevated concentrations beside the presence of the positivity of 14-3-3 and the 
increased level of NSE30. The level of α-synuclein protein, measured by 
electrochemiluminescence-based human enzyme-linked immunosorbent assay (ELISA) kit, 
was considerably elevated in sCJD cases compared to controls31,32. Furthermore, the 
confirmation of the presence of PrPSc in live patients was proposed to be included in the criteria 
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for an in vivo definite diagnosis in the future33. There are three different techniques for the 
detection of PrPSc from different body fluids34, including 1) the real-time quaking-induced 
conversion for the detection of PrPSc from the CSF35 or specimen obtained from nasal 
brushing36, 2) the protein misfolding cyclic amplification (PMCA) method for the detection of 
PrPSc from blood samples37, or 3) a specific ELISA test21,38. 
The measurement of b-amyloid peptide 1-42 (Ab1-42), tTau, and pTau proteins by ELISA 
method is available since 2009 in our institute for scientific purposes. Although the assessment 
of these 3 biomarkers may mainly have a supporting role in the clinical diagnosis of AD, but 
the above data may raise the possibility of the usefulness of particularly tTau protein in the 
diagnostic work up of CJD as well. 
The aim of the present preliminary retrospective study was to measure the levels of tTau, pTau, 
and Ab1-42 in the CSF samples of our patients with the presumptive clinical diagnosis of CJD 
from 2004 to 2017, and to assess their potential supporting diagnostic role in the context of 
other available test results (such as EEG, brain MRI, 14-3-3 protein measurement, genetic 
analysis, and neuropathological assessment). The findings of descriptive statistical analysis 
were compared with data from the biomarker literature. 
 
2. Patients, materials, and methods 
2.1 Sample collection and the work-up of clinical data 
All patients with relatively rapidly progressive dementia with suspected CJD who underwent a 
lumbar puncture since 2004 at the Department of Neurology, University of Szeged were 
enrolled to this retrospective study, following the approval of the local Ethical Committee of 
the University of Szeged (46/2014), adhering to the tenets of the most recent revision of the 
Declaration of Helsinki. For the clinical diagnosis of CJD according to the World Health 
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Organization (WHO) criteria13, in addition to the progressive dementia, the presence of the 
following 4 clinical features were assessed: myoclonus, visual or cerebellar disturbance, 
pyramidal/extrapyramidal dysfunction, and akinetic mutism. Furthermore, to be able to 
distinguish between possible and probable CJD, the available EEG and MRI findings were 
analyzed as well looking for periodic sharp wave complexes and high signal abnormalities in 
caudate nucleus and putamen or at least two cortical regions (temporal-parietal-occipital) either 
in DWI or FLAIR39, respectively, along with the qualitative determination of CSF 14-3-3 
protein with Western blot technique. The diagnosis of definite CJD was based on post-mortem 
neuropathological findings. The test results were supplemented with the data of genetic analysis 
(either PRNP gene mutation or codon 129 polymorphism) where available as well. Patients 
with relatively rapidly progressive dementia who did not meet the diagnostic criteria for CJD 
were designated as non-prion rapidly progressive dementia (npRPD). 
 
2.2 Determination of CSF total tau, phosphorylated tau, and beta-amyloid levels 
Following the lumbar puncture, the CSF samples were centrifuged at 8.000 RPM for 10 min. 
The supernatants were stored in sterile polypropylene tubes in −80°C until use, distributed into 
aliquots to avoid repeated freeze–thaw cycles. We utilized commercially available ELISA kits 
(Innogenetics N.V., now Fujirebio Europe N.V., Ghent, Belgium) for the quantitative 
determination of Ab1-42, tTau, and pTau levels according to the manufacturers’ instruction, as 
described previously40. Briefly, all samples and standards were run in duplicates, the optical 
density values were detected at 450/560 nm with a plate reader (Awareness Technology Inc., 
Palm City, FL, USA) and the respective concentrations were read from the standard curves 
fitted by Sigmaplot 10.0 software (Systat Software Inc., Richmond, CA, USA). The lower limit 
of detection of the assays was 87, 87 and 15 pg/ml for Ab1-42, tTau, and pTau, respectively. The 
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normal values provided by the reference manual are presented in the footnotes of Table 1. 
Where the measured values of tTau exceeded that of the highest standard, the actual highest 
standard values were given. Values were accepted if the respective coefficients of variation 
were less than 15%. 
Our laboratory is approved for the diagnostic analyses of tTau, pTau, and Ab1-42, by the applied 
kits, for which we could use samples running in the ‘Alzheimer's Association QC program for 
CSF biomarkers’ as quality control samples to rule out analytical bias. 
 
2.3 Statistical analyses 
The sensitivity (i.e., the number of CJD patients with alteration in the observed parameter / (the 
number of CJD patients with alteration in the observed parameter + the number of CJD patients 
without alteration in the observed parameter)) and specificity (the number of npRPD patients 
without alteration in the observed parameter / (the number of npRPD patients without alteration 
in the observed parameter + the number of npRPD patients with alteration in the observed 
parameter)) values were calculated for all the laboratory biomarkers, and for the presence of 
characteristic findings on the EEG and MRI as well. Alteration in a chemical biomarker was 
considered if the CSF level was higher than the established cut-off for tTau and pTau and lower 
than that for Ab1-42, whereas CSF 14-3-3 was considered altered when it was positive. The cut-
off values used and the method of their calculation are presented in the footnotes of Table 2. A 
descriptive statistical analysis was carried out for the sensitivity and specificity values found in 
the scientific literature for all the above-mentioned and some other biomarkers. 
 
3. Results 
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The clinical data (in light of the diagnostic criteria of CJD), the test results, and the autopsy 
findings (where applicable) of patients presenting with relatively rapidly progressive dementia 
in the period of 2004-2017 at the University of Szeged, Department of Neurology are 
demonstrated in Table 1. The proportion of genetically determined CJD among CJD cases that 
underwent genetic analysis was remarkably high (6/7), which is in line with previous data 
reporting the gCJD form to predominate in this geographical area41,42, contrasting with 
international data10. This is most probably not merely attributable to selection bias secondary 
to an influence by a positive family history, as this incidence is substantially high even if related 
to all consecutive CJD cases identified (6/12). Although, due to the limited number of cases in 
this preliminary study, a receiver operating characteristic (ROC) curve analysis cannot be 
carried out, the respective crude sensitivity and specificity values could be easily calculated by 
using the equations above, and these data are presented in Table 2. The specificity for CJD was 
found to be as surprisingly high as 100% in the cases of both the PSWCs in EEG and the 
characteristic alterations in MRI, but the sensitivity was only fair (75% and 80%, respectively). 
Among CSF biomarkers, only 14-3-3 and tTau provided 100% sensitivity (if mean + 1 SD of 
the reference values was applied as cut-off for tTau). However, the specificity of 14-3-3-
positivity was considerably poor (40%), whereas that of tTau elevation was found to be fair 
(71%). If cut-off values were changed to > 1200 pg/ml for tTau (consistent with many of the 
studies in the literature), both good sensitivity (83%) and specificity (86%) values could be 
achieved. Due to the very limited number of cases where both measurement data were available, 
only an approximation could be carried out on the utility of their combined use, providing a 
sensitivity of 87.5% and a specificity of 80%. The sensitivity values for pTau (25% in the case 
of both cut-off values) and Ab1-42 (50% and 17%, respectively) remained considerably low 
irrespective of the application of the upper quartile and the mean - 1 SD of the reference values 
as cut-offs, respectively, or > 60 pg/ml and < 400 pg/ml values (consistent with many of the 
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studies in the literature), respectively. Surprisingly, the specificity values for pTau were found 
to be good (86% in both cases), irrespective of the applied cut-off values. However, the 
specificity values for Ab1-42 remained considerably low, irrespective of the applied cut-off 
values as well (29% and 57%, respectively). 
 
4. Discussion 
CJD is a rapidly progressive, fatal neurological disorder, where only autopsy provides definite 
diagnosis. Accordingly, there is a special need for fine diagnostic tools in live patients to 
achieve accurate diagnosis as early as possible. In addition to the prognostic importance of the 
early diagnosis for the patients and their relatives, the possibility of disease transmission may 
raise hygienic considerations as well43, despite the fact that CJD cannot be transmitted through 
direct contact or airborne spread44. Accordingly, only the standard precautions are to be 
complied with by the caregivers. However, in case of iatrogenic and variant forms, the direct 
implantation or transplantation of materials of human-origin or the consumption of infected 
bovine meat may result in disease transmission44,45,46. 
As mentioned above, at present, the definite diagnosis of CJD can only be established by 
confirming pathological prion protein deposition in the brain47. However, the probabilistic 
clinical diagnosis can be supported by the presence of PSWCs in EEG and/or abnormal signal 
changes on DWI or FLAIR MRI evaluated by a qualified neuroradiologist, trained to detect the 
characteristic signs for CJD. Both methods provide good specificity (74–100%1,14,48–50 and 
85.1–100%49,51–55, respectively), confirmed by the results of the current study as well (Table 2), 
but the sensitivity values are often only fair (32–66%1,14,48–50 and 62.9–100%49,51–55, 
respectively). Accordingly, the additional utility of several chemical biomarkers of neuronal 
damage were assessed to achieve a more precise diagnosis. The most commonly used chemical 
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biomarker in CJD is the 14-3-3 protein14,17,19,29,30,34,38,56–80, the only chemical biomarker applied 
in the WHO diagnostic criteria for CJD13, with sensitivity and specificity values ranging 
between 50% and 100% (median: 89.8%) and between 43% and 100% (median: 87%), 
respectively (for more details see Table 3). Keeping in mind the heterogeneous nature of 
literature data, mainly as regards the composition of control groups, when studies using npRPDs 
as controls were selected to decrease the heterogeneity, the values remained almost the same 
(sensitivity with a median of 93.5% and specificity with a median of 83.2%). Surprisingly, data 
of the present preliminary study demonstrated a sensitivity of 100% and a specificity of 40% 
for 14-3-3 protein positivity, the opposite ends of the range found in the literature. The second 
most commonly applied biomarker is the tTau protein16,17,19,20,26,29,38,59,61,63–66,68–70,72,74,75,77–79,81–
85, which is also considered to have a possible diagnostic value in light of its relatively high 
sensitivity (ranging between 59.68% and 100% with a median of 89.2%) and specificity 
(ranging between 75.31% and 100% with a median of 92%; for more details see Table 3). The 
similar reduction of the variability of control groups to that carried out in the case of 14-3-3 
also did not considerably affect the sensitivity (median: 89.7%) and specificity (median: 
93.55%) values. With regard to the current study, if we applied the mean + 1 SD of the control 
values provided by the manufacturer as cut-off level, a considerably high (100%) sensitivity 
value was achieved but the specificity remained only fair (71%). Although the limited number 
of samples did not allow the use of ROC analysis, the increase of the cut-off value to 1200 
pg/ml, the cut-off reported in the majority of literature, resulted in the increase of specificity 
(86%) with a consequent decrease of sensitivity (83%), but in that case, both of them could be 
considered to be good. The utility of the combined use of these 2 biomarkers was assessed as 
well in some studies, resulting in a slightly decreased sensitivity (49–93%59,65,68,69,75) but a 
considerable increase in specificity (92–98%59,65,68,69,75). Due to the reduced number of data for 
this analysis, the current study could not replicate this change. The statistical comparison of 
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sensitivity and specificity values obtained in these complex studies demonstrated a significantly 
(p < 0.05) better specificity for tTau than 14-3-3. 
Less data are available about the utility of other chemical biomarkers in the diagnostic work-
up of CJD. The assessment of S100B16,17,30,59,66,68,69,72,76, NSE17,18,30,59,65,75,76, and PrP 
protein21,36,38,73,86–88 for that purpose provided sensitivity values ranging between 65% and 98% 
(median: 84.2%), 53% and 90% (median: 76.35%), and 73% and 94% (median: 81.2%), 
respectively, with specificity values ranging between 29% and 93% (median: 86.2%), 79% and 
98% (median: 92%), and 75% and 100% (median: 99.5%), respectively (for more details see 
Table 4). In light of these ranges, the diagnostic utility of these chemical biomarkers seemingly 
does not exceed those of 14-3-3 and tTau proteins; however, the considerably high median 
specificity values draw attention to more and more widespread application of the determination 
of PrP protein. 
The availability of literature data is limited with regard to the application of Ab1-42 peptide and 
pTau protein as chemical biomarkers in CJD, and it was proposed that these substances alone 
are not suitable as diagnostic markers for CJD, as their concentration values overlap with other 
neurological diseases29,81. Accordingly, with regard to Ab1-42 peptide, the comparison of CJD 
and respective control groups provided controversial results29,78,89–91. In line with these findings, 
the present study demonstrated poor sensitivity (50% or 17% if mean - 1 SD of the reference 
values provided by the manufacturer or 400 pg/ml levels were applied as cut-offs, respectively) 
and specificity values (29% or 57% if mean - 1 SD of the reference values provided by the 
manufacturer or 400 pg/ml levels were applied as cut-offs, respectively). Although the current 
study showed good specificity values for pTau (86%, either the cut-off value was calculated as 
the upper quartile of the reference values according to the manual or a cut-off value of > 60 
pg/ml was applied) similarly to those reported in the literature (ranging between 70% and 
92.13%21,82,83,85), the sensitivity values remained considerably poor (25%, either the cut-off 
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value was calculated as the upper quartile of the reference values according to the manual or a 
cut-off value of > 60 pg/ml was applied), in line with literature data ranging between 19.35% 
and 81%21,82,83,85. 
Beside the above chemical biomarkers, some promising novel ones have been recently reported 
as well, including NF-L and pNF-H27,28. The sensitivity values for NF-L and pNF-H vary 
between 80% and 100%19,20,26 and 90% and 100%, respectively19,20,26, whereas specificities 
vary between 85% and 100%, respectively19,20,26. Some recent studies31,32 have reported larger 
than 95% sensitivity and specificity values for α-synuclein when comparing sCJD with the 
control group. 
It can be concluded that despite the low number of cases, the present preliminary study 
replicated well the results of previous studies with large subject numbers. In light of the 
presented literature review, probably the measurement of 14-3-3 and tTau protein levels are the 
most widely used approaches to detect the characteristic pronounced neuronal damage in CJD. 
Recently, several attempts have been made by the application of novel chemical biomarkers to 
increase the sensitivity and specificity for the diagnosis of CJD; however, except for the 
excellent specificity values for PrP, neither of them provided reliably high values near 100%. 
Accordingly, the combination of these tests may yield the best diagnostic value, keeping in 
mind the availability and preferably low cost of the methods as well. 
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7. Figure legend 
Fig. 1. Some major physiological functions of certain chemical biomarkers, most frequently 
assessed in Creutzfeldt-Jakob disease 
 
